Morgan Stanley Pacira Bio Sciences, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Morgan Stanley holds 997,606 shares of PCRX stock, worth $26.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

997,606

Previous 1,104,774 9.7%

Holding current value

$26.7 Million

Previous $20.8 Million 19.11%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$18.33 - $27.25 $1.96 Million - $2.92 Million	-107,168 Reduced 9.7%	997,606 $24.8 Million
Q4 2024 Feb 14, 2025	SELL	$15.3 - $20.33 $7.51 Million - $9.98 Million	-491,115 Reduced 30.77%	1,104,774 $20.8 Million
Q3 2024 May 14, 2025	BUY	$11.7 - $28.46 $12.6 Million - $30.7 Million	1,079,724 Added 209.18%	1,595,889 $24 Million
Q3 2024 Nov 14, 2024	BUY	$11.7 - $28.46 $12.6 Million - $30.7 Million	1,079,724 Added 209.18%	1,595,889 $24 Million
Q2 2024 May 14, 2025	SELL	$25.5 - $31.51 $15 Million - $18.5 Million	-588,609 Reduced 53.28%	516,165 $14.8 Million
Q2 2024 Oct 17, 2024	SELL	$25.5 - $31.51 $3.93 Million - $4.86 Million	-154,162 Reduced 23.0%	516,165 $14.8 Million
Q2 2024 Aug 14, 2024	SELL	$25.5 - $31.51 $3.93 Million - $4.86 Million	-154,162 Reduced 23.0%	516,165 $14.8 Million
Q1 2024 Oct 17, 2024	BUY	$27.7 - $35.48 $4.27 Million - $5.47 Million	154,162 Added 29.87%	670,327 $19.6 Million
Q1 2024 Aug 16, 2024	SELL	$27.7 - $35.48 $415,693 - $532,448	-15,007 Reduced 2.19%	670,327 $19.6 Million
Q1 2024 May 15, 2024	SELL	$27.7 - $35.48 $415,693 - $532,448	-15,007 Reduced 2.19%	670,327 $19.6 Million
Q4 2023 Aug 16, 2024	BUY	$26.32 - $34.31 $4.45 Million - $5.8 Million	169,169 Added 32.77%	685,334 $23.1 Million
Q4 2023 Feb 13, 2024	BUY	$26.32 - $34.31 $5.9 Million - $7.69 Million	224,011 Added 48.56%	685,334 $23.1 Million
Q3 2023 Nov 15, 2023	SELL	$30.68 - $40.09 $3.01 Million - $3.93 Million	-98,033 Reduced 17.53%	461,323 $14.2 Million
Q2 2023 Aug 14, 2023	BUY	$36.12 - $47.5 $1.01 Million - $1.33 Million	28,025 Added 5.27%	559,356 $22.4 Million
Q1 2023 May 15, 2023	BUY	$35.53 - $43.38 $3.27 Million - $3.99 Million	91,961 Added 20.93%	531,331 $21.7 Million
Q4 2022 Feb 14, 2023	BUY	$38.19 - $57.45 $1.44 Million - $2.16 Million	37,582 Added 9.35%	439,370 $17 Million
Q3 2022 Nov 14, 2022	SELL	$51.24 - $58.89 $1.37 Million - $1.57 Million	-26,742 Reduced 6.24%	401,788 $21.4 Million
Q2 2022 Oct 27, 2022	BUY	$51.49 - $81.64 $7.54 Million - $12 Million	146,456 Added 51.92%	428,530 $25 Million
Q2 2022 Aug 15, 2022	BUY	$51.49 - $81.64 $7.54 Million - $12 Million	146,456 Added 51.92%	428,530 $25 Million
Q1 2022 Oct 27, 2022	SELL	$60.03 - $76.49 $8.79 Million - $11.2 Million	-146,456 Reduced 34.18%	282,074 $21.5 Million
Q1 2022 May 13, 2022	BUY	$60.03 - $76.49 $2.64 Million - $3.36 Million	43,922 Added 18.44%	282,074 $21.5 Million
Q4 2021 Feb 14, 2022	SELL	$47.97 - $62.21 $649,178 - $841,887	-13,533 Reduced 5.38%	238,152 $14.3 Million
Q3 2021 Nov 15, 2021	BUY	$54.64 - $61.3 $13.8 Million - $15.4 Million	251,685 New	251,685 $14.1 Million

Others Institutions Holding PCRX

# of Institutions

254

Shares Held

51.1M

Call Options Held

157K

Put Options Held

139K

View Full List

About Pacira BioSciences, Inc.

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $1.23B
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

More about PCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account